BioWorld

May 5, 2008

View Archived Issues

Discovery Labs Falls on Third Approvable Letter for Surfaxin

Discovery Laboratories Inc. received yet another approvable letter from the FDA for Surfaxin use in premature infants with respiratory distress syndrome, causing shares to fall more than 47 percent Friday. (BioWorld Today) Read More

Critical Therapeutics Investors Balk Over Cornerstone Merger

Read More

Study Links Gene to High Blood Sugar, Not to Type II Diabetes

Read More

Panel Supports Approval of Cinryze in Preventing in HAE

Read More

Congress Debates User Fees for Foreign Drug Inspections

Read More

Earnings Roundup

Read More

Other News To Note

Read More

Clinic Roundup

Read More